ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

Anti-B7-H3/TOP1i Antibody-drug Conjugate SYS6043

Also written as “SYS6043”, “SYS6043+PD-1/VEGF bispecific antibody” and “SYS6043 combined with PD-1/VEGF bispecific antibody ± chemotherapy.”.

Its studies are mostly in Fallopian Tube Neoplasms · Carcinoma, Hepatocellular · Neoplasms, led by 2 companies.

Drug pageAnti-B7-H3/TOP1i Antibody-drug Conjugate SYS6043: every studyAll 5 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 3, since Jun 15, 20266 company-led studies, 6 open or runningNext primary completion: Dec 30, 2027 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
CSPC Pharmaceutical Group55 open or runningphase 3since Jun 15, 2026Feb 3, 2026Dec 30, 2027phase 2 · NCT07415863
Conjupro Biotherapeuticsits history only11 open or runningphase 1since Feb 4, 2026Feb 4, 2026Dec 2029phase 1 · NCT07424547
  • Named in CSPC Pharmaceutical Group’s own pipeline as SYS6043, phase 3, as of Aug 20, 2026 (source).

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of CSPC Pharmaceutical Group only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Feb 3, 2026First study: phase 2 study in Advanced/Metastatic Solid TumorsFirst studyNCT07415863 · 820 planned · China
  2. Jun 15, 2026Phase 3 study in Platinum-resistant Ovarian CancerPhase 3 reachedNCT07708753 · 460 planned · China
  3. Jul 30, 2026Phase 2 study in Carcinoma, HepatocellularNCT07761286 · 288 planned · China
  4. Sep 16, 2026Phase 2 study in Advanced Solid TumorsNCT07833735 · 400 planned

Ahead

  1. Dec 30, 2027Primary completion: phase 2 study in Advanced/Metastatic Solid TumorsNCT07415863
  2. Oct 15, 2028Primary completion: phase 2 study in Advanced Solid TumorsNCT07833735
  3. Sep 30, 2029Primary completion: phase 2 study in Carcinoma, HepatocellularNCT07761286
  4. Oct 1, 2029Primary completion: phase 3 study in Platinum-resistant Ovarian CancerNCT07708753

TargetBeta

“An antibody-drug conjugate (ADC) composed of a monoclonal antibody directed against the immunoregulatory protein B7-homologue 3 (B7-H3, CD276) conjugated, via a cleavable linker, to a topoisomerase-1 inhibitor (TOP1i), with potential antineoplastic activity. Upon administration of anti-B7-H3/TOP1…”NCIt, read by Claude
“An antibody-drug conjugate (ADC) composed of a monoclonal antibody directed against the immunoregulatory protein B7-homologue 3 (B7-H3, CD276) ”NCIt, by rule

Other programs on CD276

ProgramCompanyFurthest phaseStudies
risvutatug rezetecanHansoh Pharmaceutical Groupphase 330
ifinatamab deruxtecanMerckphase 316
tambotatug pelitecanMediLink Therapeutics (Suzhou)phase 313
Anti-B7-H3 Antibody-drug Conjugate MHB088CruleMinghui Pharmaceuticalphase 34
Elfetabart DrozuntecanruleBioNTechphase 33
Anti-EGFR/Anti-B7-H3 Bispecific Antibody-drug Conjugate TJ101ruletj-biopharma-co-ltdphase 33
Lutetium Lu 177-DOTA-Anti-B7-H3 Monoclonal Antibody RV-01ruleradiopharm-theranostics-ltdphase 21
Autologous Anti-B7-H3 CAR T-cells BCB-276rulebrainchild-bio-incphase 21
Anti-B7-H3/CD28 Bispecific Antibody XmAb808ruleXencorphase 12
Anti-B7-H3/Anti-PTK7-TOP1i Bispecific Antibody-drug Conjugate IDE034ruleideaya-biosciencesphase 11
Anti-B7-H3/Anti-ROR1-Exatecan Bispecific Antibody-drug Conjugate NEOK001ruleneok-bio-incphase 11
HLX316Fosun Pharmaphase 11

Studies

All 4 CSPC Pharmaceutical Group leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07833735Advanced Solid Tumors2Not yet recruitingOct 15, 2028400
NCT07761286Carcinoma, Hepatocellular · China2Not yet recruitingSep 30, 2029288
NCT07708753Platinum-resistant Ovarian Cancer · China3RecruitingOct 1, 2029460
NCT07415863Advanced/Metastatic Solid Tumors · China2RecruitingDec 30, 2027820

How it is read

Names in the registry

  • “SYS6043”, 4 entries
  • “SYS6043+PD-1/VEGF bispecific antibody”, 1 entry
  • “SYS6043 combined with PD-1/VEGF bispecific antibody ± chemotherapy.”, 1 entry
  • “SYS6043 monotherapy”, 1 entry
  • “SYS6090 Injection +SYS6043 Injection +Bevacizumab Injection”, 1 entry

Codes read as this program: SYS6043.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.